ACC.25: Focus on ATTR-CM
Novel cardiology innovations and science from the American College of Cardiology 2025, taking place March 29-31, 2025, in Chicago, IL.
Sudden cardiac death increases amid lower daily temperatures.
Acoramidis therapy significantly increases serum transthyretin in people with ATTR-CM compared with tafamidis.
Patients with single ventricle heart disease commonly have mental health diagnoses.
Acoramidis therapy induces a significant increase in serum transthyretin, which is typically lower in ATTRv-CM.
Advertisement